Edward Rapp Net Worth

The estimated Net Worth of Edward J Rapp is at least $911 mil dollars as of 3 March 2020. Mr. Rapp owns over 2,875 units of Abbvie Inc stock worth over $559,446 and over the last 17 years he sold ABBV stock worth over $0. In addition, he makes $352,029 as Independent Director at Abbvie Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Rapp ABBV stock SEC Form 4 insiders trading

Edward has made over 22 trades of the Abbvie Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 2,875 units of ABBV stock worth $252,626 on 3 March 2020.

The largest trade he's ever made was exercising 60,000 units of Abbvie Inc stock on 31 January 2014 worth over $2,317,800. On average, Edward trades about 2,637 units every 36 days since 2008. As of 3 March 2020 he still owns at least 2,875 units of Abbvie Inc stock.

You can see the complete history of Mr. Rapp stock trades at the bottom of the page.

Edward Rapp biography

Edward J. Rapp is an Independent Director of the Company. Mr. Rapp served as the Caterpillar Inc. group president for resource industries from 2014 until his retirement in mid-2016. He previously served at Caterpillar as group president based in Singapore in 2013 and 2014 and as the chief financial officer from 2010 to 2013, and he was named a group president in 2007. Mr. Rapp is presently a board member for FM Global. He is currently a member of the University of Missouri College of Business Strategic Development Board.

What is the salary of Edward Rapp?

As the Independent Director of Abbvie Inc, the total compensation of Edward Rapp at Abbvie Inc is $352,029. There are 13 executives at Abbvie Inc getting paid more, with Richard Gonzalez having the highest compensation of $21,610,600.

How old is Edward Rapp?

Edward Rapp is 61, he's been the Independent Director of Abbvie Inc since 2013. There are 10 older and 22 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.

What's Edward Rapp's mailing address?

Edward's mailing address filed with the SEC is North Waukegan Road, North Chicago, Lake County, Illinois, 60044, United States.

Insiders trading at Abbvie Inc

Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell y Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.

What does Abbvie Inc do?

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Complete history of Mr. Rapp stock trades at Abbvie Inc y Caterpillar

Abbvie Inc executives and stock owners

Abbvie Inc executives and other stock owners filed with the SEC include:

• Richard Gonzalez,
  Chairman of the Board, Chief Executive Officer
• Laura Schumacher,
  Vice Chairman, External Affairs and Chief Legal Officer
• Carlos Alban,
  Vice Chairman, Chief Commercial Officer
• Michael Severino,
  President, Vice Chairman
• Robert Michael,
  Chief Financial Officer, Senior Vice President
• William Chase,
  Executive Vice President - Finance and Administration
• Richard A. Gonzalez,
  Chairman & CEO
• Dr. Michael E. Severino,
  Vice Chairman & Pres
• Laura J. Schumacher,
  Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.
• Timothy Richmond,
  Chief Human Resource Officer, Executive Vice President
• Robert A. Michael,
  Vice Chairman of Fin. & Commercial Operations and CFO
• Glenn Tilton,
  Lead Independent Director
• Robert Alpern,
  Independent Director
• Edward Rapp,
  Independent Director
• Brett Hart,
  Independent Director
• William Burnside,
  Independent Director
• Roxanne Austin,
  Independent Director
• Frederick Waddell,
  Independent Director
• Melody Meyer,
  Independent Director
• Edward Liddy,
  Independent Director
• Thomas Freyman,
  Independent Director
• Rebecca Roberts,
  Independent Director
• Brian Durkin,
  Vice President, Controller
• Jeffrey Stewart,
  Senior Vice President, U.S. Commercial Operations
• Nicholas Donoghoe,
  Senior Vice President - Enterprise Innovation
• Azita Saleki-Gerhardt,
  Executive Vice President - Operations
• Henry Gosebruch,
  Executive Vice President, Chief Strategy Officer
• Scott T. Reents,
  Sr. VP & CFO
• Jeffrey Ryan Stewart,
  Exec. VP & Chief Commercial Officer
• Henry O. Gosebruch,
  Exec. VP & Chief Strategy Officer
• Scott C. Brun M.D.,
  VP of Scientific Affairs & Head of AbbVie Ventures
• Timothy J. Richmond,
  Exec. VP & Chief HR Officer
• Elizabeth Shea,
  VP of Investor Relations
• Dr. Thomas J. Hudson,
  Sr. VP of R&D and Chief Scientific Officer
• Dr. Azita Saleki-Gerhardt,
  Exec. VP of Operations
• Thomas A. Hurwich,
  VP, Controller
• Jennifer L. Davis,
  
• Roy S Roberts,
  Director
• Laboratories Abbott,
  10% owner
• John M Leonard,
  SVP, Chief Scientific Officer
• Elaine K. Sorg,
  SVP, US COMMERCIAL OPERATIONS
• Perry C Siatis,
  EVP, GC AND SECRETARY
• Carrie C Strom,
  SVP & PRES GLOBAL ALLERG AESTH
• Thomas J Hudson,
  SVP, CSO, GLOBAL RESEARCH
• Scott T Reents,
  EVP, CHIEF FINANCIAL OFFICER
• Susan E Quaggin,
  
• Kevin K Buckbee,
  SVP, CONTROLLER
• Roopal Thakkar,
  SVP, CMO, GLOBAL THERAPEUTICS